Medical marijuana will hit Big Pharma hard if legalized in the United States
Following the historic move by Canada this week to legalize marijuana for recreational use, pressure is now mounting for the United States to follow suit.
Currently, marijuana is legal for medical use in just a handful of US States.
But what is holding the US back from legalizing pot for medicinal use, even if it’s not yet prepared to fully embrace it for recreation?
Answer: Money, greed, power, control etc…
Or to put it simply; Big Pharma.
The pharmaceuticals industry is one of the largest and most profitable in the world.
The legalization of an unpatentable natural product onto the market would literally cost the drug companies billions of dollars of losses.
According to Dr. John Regan, pharmaceutical companies are one of the biggest influences on the US economy and, subsequently, in US law.
It is no secret that Big Pharma has lobbied against medical (and recreational) marijuana legalization as they stand to lose a substantial amount of money.
States that have already legalized medical cannabis are already seeing the effects: prescription drug use has decreased by an average of 11 percent.
The National Academies of Science keeps track of the conditions most effectively treated with medical marijuana, and nearly all of them have high-profit prescription counterparts.
Among the conditions are glaucoma, chronic pain, nerve disorders/pain, post-traumatic stress disorder, anxiety, sleep disorders, and nausea/vomiting associated with chemotherapy.
Big Pharma is an incredibly powerful and lucrative industry.
While $18.5 billion in losses over a three year period may seem enormous, “medical cannabis would be a drop in the bucket when it comes to impacting the total pharmaceutical industry,” according to Giadha Aguirre De Carcer, founder, and CEO of New Frontier Data.
Marijuana is legal for medical purposes in 29 states
According to Vox, twenty-nine states and Washington, DC, allow marijuana for medical purposes, although their approaches can significantly differ.
Some allow medical marijuana dispensaries and home cultivation.
Others only allow home cultivation.
And a few allow dispensaries but not home cultivation.
There’s a growing body of research supporting marijuana’s use for medical purposes.
Some studies and anecdotal evidence suggest marijuana can be used for various medical problems, including pain, nausea and loss of appetite, Parkinson’s disease, inflammatory bowel disease, PTSD (post-traumatic stress disorder), epilepsy, and multiple sclerosis.
But a review of the evidence published in the Journal of the American Medical Association found little evidence for marijuana’s ability to treat health conditions outside chronic pain and muscle stiffness from multiple sclerosis.
The rationale for this is simple: Studies show medical marijuana can effectively treat chronic pain, which opioids are commonly used for.
But unlike opioids, medical marijuana cannot cause deadly overdoses.
So medical marijuana could supplant some opioid use and save some lives.
Medical marijuana legalization also has a lot of popular support: A 2010 Pew Research Center survey found that 73 percent of American voters back medical marijuana, including 80 percent of Democrats, 76 percent of independents, and 61 percent of Republicans.
But the federal government doesn’t recognize marijuana’s medical potential, largely because the studies have been small so far, and there have been no large-scale clinical trials proving pot’s medicinal value.
Behind that judgment, though, lies a bit of a catch-22: It’s long been difficult to conduct thorough studies on the medical uses of marijuana because of the drug’s prohibition and the need for approval from a federal government that hasn’t been very interested in studying marijuana’s potential benefits.
So the federal government is demanding scientific research proving marijuana has medical value, but the federal government’s restrictions make it difficult to conduct that research.
For legalization advocates, getting the federal government to acknowledge marijuana’s medical value could be a significant step forward.
For one, it would push the Drug Enforcement Administration to reclassify marijuana from a schedule 1 to a schedule 2 substance, which could relax some of the restrictions on the drug.
That alone would amount to a huge symbolic shift: After decades of scheduling marijuana in the strictest possible category, a downgrade could be taken as an acknowledgment by the federal government that its old policies have failed.